Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Redhill Biopharma Ltd (NASDAQ: RDHL).

Full DD Report for RDHL

You must become a subscriber to view this report.


Recent News from (NASDAQ: RDHL)

RedHill Biopharma up 7% on announcing positive End-of-Phase II meeting with FDA on BEKINDA for IBS-D
RedHill Biopharma (NASDAQ: RDHL ) has recently concluded a positive End-of-Phase II/Pre-Phase III (Type B) meeting with the FDA discussing the clinical and regulatory pathway towards potential U.S. approval of BEKINDA (RHB-102) for the treatment of diarrhea-predominant irrit...
Source: SeekingAlpha
Date: September, 12 2018 08:51
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA ® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders In light of the clarity provided by the FDA regarding the clinical and r...
Source: GlobeNewswire
Date: September, 12 2018 07:00
Your Daily Pharma Scoop: Spectrum Positive, Xenon Expands, ViiV's Label Receives FDA Clearance
Stocks in News: SPPI, XENE Spectrum Pharma's poziotinib continues to show positive action Discussion : Spectrum Pharmaceuticals ( SPPI ) reported its plan to present updated data from a Phase 2 clinical trial of poziotinib in EGFR exon 20-mutant non-small cell lung cancer (N...
Source: SeekingAlpha
Date: September, 10 2018 00:02
RedHill Biopharma advances to second stage of Phase IIa study with YELIVA for cholangiocarcinoma
RedHill Biopharma Ltd. (NASDAQ: RDHL ) announces that the ongoing single-arm Phase IIa study with orally-administered YELIVA (opaganib, ABC294640) for the treatment of advanced cholangiocarcinoma (bile duct cancer) has achieved its pre-specified efficacy goal for the first stage ...
Source: SeekingAlpha
Date: September, 06 2018 09:38
RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
The first stage of the Phase IIa study with YELIVA ® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its second stage, enrolling the full cohort of 39 evaluable patien...
Source: GlobeNewswire
Date: September, 06 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-147.558.118.117.50120,210
2017-02-039.589.599.599.456,986
2017-02-029.689.419.919.4132,474
2017-02-019.759.689.889.6021,829
2017-01-319.699.779.839.56104,277

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-143,58819,34718.5455Cover
2018-12-138,96031,07728.8316Cover
2018-12-1213,66929,66946.0717Short
2018-12-112,59772,0853.6027Cover
2018-12-108,39053,36115.7231Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RDHL.


About Redhill Biopharma Ltd (NASDAQ: RDHL)

Logo for Redhill Biopharma Ltd (NASDAQ: RDHL)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: RDHL)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: September, 12 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: September, 06 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: September, 04 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: August, 30 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: August, 24 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: August, 20 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: August, 14 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: August, 13 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: August, 13 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: August, 10 2018

       

       


      Daily Technical Chart for (NASDAQ: RDHL)

      Daily Technical Chart for (NASDAQ: RDHL)


      Stay tuned for daily updates and more on (NASDAQ: RDHL)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: RDHL)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RDHL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RDHL and does not buy, sell, or trade any shares of RDHL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/